Eli Lilly & Co. (LLY) News and Global Pharmaceutical Innovation Updates

1,443.17
10.06
0.70 %
Daily range
Weekly range
  • Igor Krasulya
  • 11.11.2026
Eli Lilly shares weekly forecast: Recovery supported by bullish momentum indicators
Shares of Eli Lilly and Company (LLY) are trading near $1,431 after gaining roughly 5% over the past week, supported by steady demand for the company's new drug lines. ...
  • Sholanke Dele
  • 09.11.2026
Eli Lilly Foundayo phase 3 milestone: Can LLY sustain its rally?
Eli Lilly (LLY) stock is trading at $1,410, rising 3.49% on the day. The stock remains positioned above its key moving averages, reflecting continued underlying ...
  • Dmytro Kharkov
  • 05.11.2026
Will Eli Lilly stock hold the $1,356 support as sellers dominate after price drop?
Eli Lilly (LLY) stock is trading at $1,371, down 3.2% on the day. The price sits below its key short- and medium-term moving averages, with additional downside momentum ...
  • Dmytro Kharkov
  • 04.11.2026
Eli Lilly stock weekly forecast: Support at $1,284 comes into focus after recent gains
Shares of Eli Lilly and Company (LLY) are trading near $1,409 as the weekly recovery holds, but momentum is stretched. Attention turns to whether support can withstand ...
  • Anastasiia Chabaniuk
  • 30.10.2026
Eli Lilly quarterly earnings beat and guidance boost: Can LLY continue gains?
Eli Lilly (LLY) stock is trading at $1,434, up 4.41% on the day. The price is well above its key moving averages, reflecting clear bullish momentum at multiple ...
  • Anastasiia Chabaniuk
  • 29.10.2026
Can strong GLP-1 drug sales fuel Eli Lilly stock?
Eli Lilly (LLY) stock is trading at $1,378, marking a daily gain of 6.87%. The price sits above its short- and medium-term moving averages as well as long-term averages, ...
  • Jainam Mehta
  • 28.10.2026
Eli Lilly shares weekly forecast: Buyers maintain control with focus on upcoming earnings and technical stability
Shares of Eli Lilly and Company (LLY) are trading near $1,280 as buyers continue to hold control going into the week. Stable gains, without significant movement, set the ...
  • Jainam Mehta
  • 23.10.2026
LLY declines as overbought conditions weigh on upward momentum
Eli Lilly (LLY) stock is trading at $1,265, marking a decline of 3.2% for the day. The share price is currently below its short-term moving average but still holds above ...
  • Ashutosh Sureka
  • 22.10.2026
Eli Lilly expands GLP-1 medicines distribution with Mubadala Bio: Can LLY continue gains?
Eli Lilly (LLY) stock is trading at $1,313, up 3.33% on the day and sitting near its session high. The price is positioned above its key moving averages, reflecting ...
  • Hlib Chabaniuk
  • 21.10.2026
Eli Lilly shares weekly forecast: Strong demand for obesity drugs supports sustained gains
Shares of Eli Lilly and Company (LLY) are trading near $1,286 after climbing about 2% this week, as the recovery holds despite signs of an overstretched setup. Momentum ...
  • Oleg Tkachenko
  • 20.10.2026
Eli Lilly shares technical analysis: Buyer support and recovery attempt set the tone
Eli Lilly (LLY) stock is trading at $1,295, up 4.46% on the day and closing near its session high. The price remains above its key short- and long-term moving averages, ...
  • Parshwa Turakhiya
  • 15.10.2026
Will Eli Lilly stock break resistance as earnings and ETF inflows drive strong sentiment?
Eli Lilly (LLY) stock is trading at $1,264, up 4.4% on the day and currently near the session high. The price sits above its key moving averages, indicating solid ...
  • Yaroslav Dmytrenko
  • 14.10.2026
Eli Lilly reports robust Q2 results: Can LLY sustain its upward momentum?
Eli Lilly (LLY) stock is trading at $1,210, up 3.79% on the day, and holding above its key moving averages.[assets-prediction-widget][highlights-block]Blockbuster drug ...
  • Viktoras Karapetjanc
  • 13.10.2026
Eli Lilly stock weekly forecast: Overbought Stochastic RSI limits upside within narrow range
Shares of Eli Lilly and Company (LLY) are trading near $1,176 as the recovery setup carries into the coming week. A quiet week, with little change in price, leaves the ...
  • Dmytro Kharkov
  • 13.10.2026
Roche licenses obesity drug candidate from China’s Rona Therapeutics in deal worth up to $1.16 billion
Roche is expanding its push into the fast-growing obesity treatment market with a licensing agreement for an experimental drug candidate from China-based Rona Therapeutics. The deal gives the ...
  • Viktoras Karapetjanc
  • 08.10.2026
Eli Lilly stock faces weak momentum: Technical outlook
Eli Lilly (LLY) stock is trading at $1,152, down 3.03% on the day. The price has moved below its near-term moving averages but still holds above longer-term ...
  • Parshwa Turakhiya
  • 07.10.2026
Why is Eli Lilly stock up 3.4% today?
Eli Lilly and Company (LLY) surged 3.44% after strong financial results and upbeat guidance drew fresh buying interest. The rally is supported by Eli Lilly's bullish momentum above key moving ...
  • Mykhailo Ihnatenko
  • 07.10.2026
Foundayo delivers positive data: LLY resistance levels in focus
Eli Lilly (LLY) stock is trading at $1,202, up 3.85% on the day and sitting above its key moving averages, reflecting strong positive ...
  • Andrey Mastykin
  • 06.10.2026
Eli Lilly stock weekly forecast: rebound odds rise as Stochastic RSI enters oversold zone
Shares of Eli Lilly and Company (LLY) are trading near $1,156 after a robust week that lifted the stock almost 2%. Buyers were unable to confirm a clean breakout as ...
  • Ivan Andriyenko
  • 30.09.2026
Wall Street stocks head for quarterly gains as Lilly trial data weighs on shares
U.S. equities are ending September and the third quarter with gains, as the S&P 500 and Nasdaq rise despite higher oil prices and longer-dated Treasury yields. The late-session focus is also ...
  • Hlib Chabaniuk
  • 29.09.2026
Eli Lilly stock weekly forecast: Price action consolidates as support at $1,177 stays in focus
Shares of Eli Lilly and Company (LLY) are trading near $1,180 as a recovery setup holds, but price action remains stretched heading into the week. Corporate developments ...